Our Pricing

What Results Can You Expect Long Term?

Published on: June 03, 2026

Understanding weight loss injection results long term UK is essential before starting treatment. At Cured Pharmacy, our clinical team has supported thousands of patients through sustained weight management journeys with Mounjaro, Wegovy, and Saxenda. Clinical trial data spanning 72 weeks and beyond demonstrates that these medications, when combined with lifestyle changes, can maintain substantial weight reduction over extended periods [1][2].

Long-Term Weight Loss Injection Results: What Clinical Trials Show

The most comprehensive long-term data comes from the SURMOUNT-1 trial for tirzepatide (Mounjaro) and the STEP trials for semaglutide (Wegovy). In SURMOUNT-1, patients receiving the 15mg tirzepatide dose achieved an average 22.5% total body weight reduction at 72 weeks, with the majority maintaining or continuing to lose weight throughout the study period [1]. This represents one of the highest sustained weight reductions ever recorded in obesity pharmacotherapy.

The STEP-1 trial demonstrated that patients on semaglutide 2.4mg (Wegovy) maintained an average 14.9% body weight reduction at 68 weeks, with 86.4% of participants losing at least 5% of their initial weight [2]. Critically, weight loss plateaued around weeks 60-68 rather than rebounding, suggesting metabolic adaptation rather than treatment failure.

For liraglutide 3.0mg (Saxenda), the SCALE trial followed patients for 56 weeks, showing an average 8% body weight reduction with daily injections [3]. While lower than dual-pathway treatments, Saxenda demonstrated consistent appetite suppression throughout the study period, making it suitable for patients who respond well to GLP-1-only mechanisms.

What Happens After the First Year on Weight Loss Injections?

Extension studies provide crucial insight into outcomes beyond the initial trial periods. The SURMOUNT-1 extension data shows that patients who continued tirzepatide maintained their weight loss through 104 weeks, with minimal regain when adherence remained high [1]. This challenges the outdated notion that injectable weight loss treatments only produce temporary results.

However, discontinuation studies paint a different picture. When patients stopped semaglutide after 68 weeks in the STEP-1 withdrawal trial, they regained approximately two-thirds of their lost weight within 52 weeks [4]. This underscores a fundamental principle: these medications work by modifying appetite signalling and metabolic hormones—effects that diminish when treatment stops.

Maintaining Results: The Role of Lifestyle Integration

Long-term success requires integrating medication with sustainable behavioural changes. Our clinical experience at Cured Pharmacy shows that patients who establish new eating patterns and activity routines during the initial treatment phase tend to maintain better outcomes if they later reduce or stop medication. The injection creates a metabolic window where appetite is reduced and satiety signals are restored—making it easier to adopt healthier habits that can persist independently.

Mounjaro Long-Term Results: The Dual-Pathway Advantage

Mounjaro's dual GIP/GLP-1 receptor mechanism produces distinctly different long-term outcomes compared to single-pathway treatments. The GIP component enhances insulin secretion and may improve fat metabolism, while the GLP-1 component reduces appetite and slows gastric emptying [1]. This combination appears to produce more durable weight loss over extended periods.

In head-to-head comparisons, tirzepatide consistently outperformed semaglutide at equivalent time points. At 40 weeks in the SURPASS-2 trial, patients on 15mg tirzepatide lost an average of 5.5kg more than those on 1mg semaglutide [5]. The gap widened over time, suggesting that dual-pathway activation may prevent the metabolic adaptation that sometimes limits single-pathway treatments.

Patients starting Mounjaro at Cured Pharmacy from £135.00 undergo gradual dose escalation over 16-20 weeks to reach maintenance dosing. This titration schedule, while slower than some alternatives, significantly reduces gastrointestinal side effects and improves long-term adherence—a critical factor in sustained outcomes.

Realistic Expectations for Tirzepatide Over Two Years

Based on extension trial data, patients who remain on the maximum tirzepatide dose can expect to maintain 20-25% body weight reduction through two years, provided adherence remains consistent [1]. Weight typically stabilises between months 16-20 rather than continuing to decline indefinitely. This plateau represents a new metabolic set point rather than treatment failure, and maintaining this reduced weight still delivers substantial health benefits including improved cardiovascular markers and reduced diabetes risk.

Wegovy and Saxenda: Long-Term Outcomes Compared

Wegovy (semaglutide) and Saxenda (liraglutide) represent first-generation and previous-generation GLP-1 treatments respectively, each with distinct long-term profiles. Wegovy's once-weekly dosing improves adherence compared to Saxenda's daily injections, and this translates into better sustained outcomes in real-world settings [2][3].

The STEP trials showed that Wegovy patients maintained an average 14.9% weight reduction at 68 weeks, compared to Saxenda's 8% at 56 weeks in the SCALE trials [2][3]. However, these figures represent averages—individual responses vary considerably based on baseline metabolic health, adherence, and lifestyle factors. Some patients respond exceptionally well to liraglutide's continuous GLP-1 stimulation, particularly those with strong appetite-driven eating patterns.

At Cured Pharmacy, Wegovy is available from £135.00 (currently reduced from £135.00) and Saxenda from £135.00, both requiring a free online consultation with a UK prescriber. The choice between them depends on your medical history, injection preference, and how your body responds to the initial doses. Our clinical team monitors progress through follow-up assessments to optimise your treatment pathway.

Weight Loss Injection Results Over Time: Month-by-Month Progression

Understanding the typical timeline helps set realistic expectations. In the first 4-8 weeks, patients usually experience moderate weight loss (2-4% of body weight) as doses are gradually increased and appetite begins to normalise. Gastrointestinal side effects like nausea are most common during this titration phase but typically improve with continued use [1][2].

Weeks 12-24 represent the period of most rapid weight loss, with patients typically losing 8-12% of their starting weight as they reach therapeutic doses. Appetite suppression is most pronounced during this phase, and many patients report feeling satisfied with smaller portions and reduced food preoccupation. This is the optimal window for establishing new eating habits that support long-term maintenance.

Beyond 6 months, weight loss continues but at a slower rate, typically reaching a plateau between months 16-20. This plateau does not indicate treatment failure—it represents your body reaching a new equilibrium at a lower weight. Maintaining this reduced weight delivers ongoing health benefits including improved cardiovascular risk markers, better glycaemic control, and reduced joint stress [1][2].

What If Weight Loss Stalls Before Target?

Plateaus before reaching your target weight sometimes occur, particularly if caloric intake gradually increases as side effects diminish. Our prescribers at Cured Pharmacy can assess whether dose adjustment, treatment switching, or enhanced lifestyle support might help overcome the plateau. Some patients benefit from adding structured meal planning or increasing physical activity during plateau periods to restart progress.

Choosing the Right Weight Loss Treatment for Long-Term Success

Selecting between Mounjaro, Wegovy, Saxenda, or oral alternatives like Orlistat depends on your medical history, weight loss goals, budget, and tolerance for injections. Mounjaro currently demonstrates the highest average weight loss in clinical trials but requires once-weekly injections and costs more than alternatives [1]. Wegovy offers a middle ground with strong efficacy and once-weekly dosing. Saxenda suits patients who prefer daily dosing or have medical reasons to avoid higher-potency treatments.

Oral medications like Orlistat (from £135.00) and Xenical work through a completely different mechanism—blocking fat absorption rather than modifying appetite hormones. They produce more modest weight loss (average 5-8% over 12 months) but avoid injection-related side effects and cost significantly less [6]. For some patients, starting with Orlistat and progressing to injectables if needed provides a logical stepped approach.

All prescription weight loss medications available at Cured Pharmacy require a clinical assessment by a UK-registered prescriber. Our online consultation takes under 3 minutes and reviews your medical history, current medications, and weight loss goals to determine the most appropriate treatment. Superintendent Pharmacist Tarun Kumar (GPhC 2233073) and our clinical team ensure every prescription meets MHRA safety standards and NICE guidelines.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
4. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
5. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
6. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to treatment and lifestyle modifications. Clinical trial data represents average outcomes and individual results may differ.